ClinicalTrials.gg
CompletedNCT06639997Updated Jan 30, 2026

Safety and Tolerability of AZD5148 in Japanese Participants

A Phase 1 interventional study of AZD5148 and Placebo in Clostridioides Difficile Infection, sponsored by AstraZeneca. Completed at 1 site in Japan. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by AstraZeneca · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to measure safety, tolerability and PK of a single dose of AZD5148 administered via IV bolus or IM injection in healthy Japanese participants.

Read the detailed description

The purpose of this study is to measure safety, tolerability and PK of a single dose of AZD5148 administered via IV bolus or IM injection in healthy Japanese participants.

Study details include:

  • There will be 12 planned visits (including screening visit) over a period of up to 56 weeks.
02

Conditions studied

  • Clostridioides Difficile Infection
03

In context

Clostridium Infections

251 studies on the registry are indexed under Clostridium Infections; 51 are open to participants now.

This study's enrollment of 16 is below the median of 64 across 185 interventional studies indexed under Clostridium Infections.

Browse Clostridium Infections studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be Japanese male or female and aged 18-65 years inclusive at the time of signing the .
  • Participants who are overtly healthy, as determined by medical evaluation, including medical history, physical examination and baseline safety laboratory studies, according to the judgement of the investigator.
  • without abnormalities at screening.
  • Able to complete the Follow-up Period through Day 361 as required by the protocol.
  • No medical history of symptomatic C. difficile infection within the prior 2 years.
  • Participants must be medically stable, defined as disease not requiring significant change in therapy or hospitalisation or worsening disease during the 1 month prior to enrolment, with no acute change in condition at the time of study enrolment as judged by the Investigator.
  • Able to understand and comply with study requirements/procedures based on the assessment of the Investigator.
  • Body weight within the range of 45 to 110 kg and (BMI) within the range of 18.0 to 32.0 kg/m2 (inclusive) at screening.
  • use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    1. Women of no are defined as women who are either permanently sterilised or . Women will be considered postmenopausal if they have been amenorrhoeic for 12 months prior to the planned date of randomisation without an alternative medical cause. The following age-specific requirements apply:

      • Women \< 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following the cessation of exogenous hormonal treatment and follicle-stimulating hormone levels in the postmenopausal range.
      • Women ≥ 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following the cessation of all exogenous hormonal treatment.
    2. Female participants of childbearing potential must use one highly effective form of birth control. A highly effective method of contraception is defined as one that can achieve a failure rate of less than 1% per year when used consistently and correctly. Women of childbearing potential who are sexually active with a non-sterilised male partner must agree to use one highly effective method of birth control from 3 months prior to IMP administration and agree to continue through 360 days following IMP administration. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, withdrawal, spermicides only and lactational amenorrhoea method are not acceptable methods of contraception. Female condom and male condom should not be used together. All women of childbearing potential must have negative results of pregnancy tests prior to dosing.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Previous , infusion-related reaction or severe adverse reaction following mAb administration.
  • Abnormal vital signs after 5 minutes of supine rest, at Screening and/or admission to the study site.
  • Any abnormalities in laboratory values at the Screening Visit.
  • Clinically significant bleeding disorder or prior history of significant bleeding or bruising following IM injections or venipuncture
  • Primary or acquired immunodeficiency, including infection, or due to drugs, including any course of therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months prior to screening. Any known HIV infection at screening
  • Any known or C virus infection at screening
  • History of other than treated non-melanoma skin cancers or locally treated cervical cancer in the previous 5 years
  • Any laboratory value in the screening panel that, in the opinion of the investigator, is clinically significant or might confound analysis of study results
  • Absence of suitable veins for blood sampling and IMP administration
  • Receipt of immunoglobulin or blood products, or expected receipt, within 6 months prior to screening or expected to receive during the study
  • Previous receipt of an mAb within 6 months or five antibody half-lives (whichever is longer), prior to date
  • Receipt of any products in the preceding 90 days or expected receipt of investigational product during the period of study follow-up or concurrent participation in another interventional study
  • Participants with a known hypersensitivity to any component of the IMP
  • History of allergic disease or reactions likely to be exacerbated by any component of the IMP
  • Blood drawn in excess of a total of 400 mL (1 unit) for any reason within 3 months prior to screening or plan to donate blood until the end of follow-up period
  • History of alcohol or drug abuse within the past 2 years that, according to the investigator, might affect the assessments of safety or ability the of participant to comply with all study requirements
  • Deprived of freedom by an administrative or court order, in an emergency setting or hospitalised involuntarily
  • Any condition that, in the opinion of the investigator, might compromise participant safety or interfere with the evaluation of the IMP or interpretation of participant safety or study results. The investigator should follow the standard vital sign ranges
  • Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restriction sand requirements.
  • Previous randomisation in the present study.
  • For females only - currently pregnant or breast-feeding.
  • Employees of the sponsor, study site or any other individuals involved with the conduct of the study or immediate family members of such individuals.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Cohort 1 - AZD5148 IM

    Biological: AZD5148 (Cohort 1) ・Single dose of AZD5148 IM

    Drug: AZD5148

  • Placebo comparator
    Cohort 1 - Placebo IM

    Biological: Placebo (Cohort 1) Single dose of Placebo IM

    Drug: Placebo

  • Experimental
    Cohort 2 - AZD5148 IV

    Biological: AZD5148 (Cohort 2) ・Single dose of AZD5148 IV

    Drug: AZD5148

  • Placebo comparator
    Cohort 2 - Placebo IV

    Biological: Placebo (Cohort 2) Single dose of Placebo IV

    Drug: Placebo

Interventions

  • Participants will receive AZD5148 as IM injection or IV bolus

  • DrugPlacebo

    Participants will receive matching doses of placebo as an IM injection or IV bolus

06

What researchers measure

Primary outcomes

  1. Number of Japanese participants with adverse events (AEs).

    To evaluate the safety and tolerability of AZD5148 administered as a single IV or IM dose to healthy Japanese adult participants.

    Time frame: From Randomization (Day -1 or Day 1) to Day 91

  2. Number of participants with serious adverse events (SAEs)

    To evaluate the safety and tolerability of AZD5148 administered as a single IV or IM dose to healthy Japanese adult participants.

    Time frame: From Screening (Day -28 to Day -2) to final Follow-up Visit (Day 361)

  3. Number of participants with adverse events of special interest (AESIs)

    To evaluate the safety and tolerability of AZD5148 administered as a single IV or IM dose to healthy Japanese adult participants.

    Time frame: From Randomization (Day -1 or Day 1) to final Follow-up Visit (Day 361)

Secondary outcomes

  1. Maximum observed drug concentration (Cmax)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361)

  2. Time to reach maximum observed concentration (tmax)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 days)

  3. Time of last quantifiable concentration (tlast)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 days)

  4. Terminal elimination half-life, estimated as (ln2)/λz (t1/2λz)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 days)

  5. Area under concentration-curve from time 0 to the time of last quantifiable concentration (AUClast)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 days)

  6. Area under concentration-time curve from time 0 extrapolated to infinity (AUCinf)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 days)

  7. Volume of distribution at steady state (IV administration only) (Vss)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 days)

  8. Volume of distribution at terminal phase (IV administration only) (Vz)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 days)

  9. Systematic clearance (IV administration only) (CL)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 days)

  10. Apparent total body clearance (IM administration only) (CL/F)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 days)

  11. Apparent volume of distribution based on the terminal phase (IM administration only) (Vz/F)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 days)

  12. Bioavailability for extravascular administration (IM administration only) (F)

    To evaluate the single dose PK of AZD5148.

    Time frame: From Day 1 until last Follow up visit (Day 361 days)

  13. Incidence of positive ADAs against AZD5148 in serum

    To evaluate the ADA responses to a single IV or IM dose of AZD5148.

    Time frame: Day 1 (pre-dose), Day 29, Day 91, Day 181 and Day 361

07

Study locations

1 site
  • Research Site
    Sumida-ku, 130-0004, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Dec 2025, 13 months.

Of 14 phase 1 interventional studies under Clostridium Infections, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2024
First posted
Oct 15, 2024
StartActual
Oct 31, 2024
Primary completionActual
Dec 25, 2025
CompletionActual
Dec 25, 2025
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06639997
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Oct 31, 2024
Primary completion
Dec 25, 2025
Completion
Dec 25, 2025
Last update
Jan 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ombetoxabart

Start the discussion